Form 4: PTGX Director Sells Shares After Option Exercise

Protagonist Therapeutics Director Harold E. Selick exercised options and sold 24,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Director Harold E. Selick engaged in transactions involving Protagonist Therapeutics, Inc. common stock.
• Selick exercised 24,000 fully vested stock options at an exercise price of $12.88 per share.
• Concurrently, Selick sold 24,000 shares of common stock at a price of $105 per share.
• These transactions were conducted on March 26, 2026, under a Rule 10b5-1 trading plan.
• Following these transactions, Selick directly owns 60,845 shares of Protagonist Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a 10b5-1 plan, reflecting an executive monetizing vested equity rather than a bearish signal. The significant profit realized from the option exercise is a positive for the individual.

Positives

• Director Selick realized a significant gain by exercising options at $12.88 and selling shares at $105.00.
• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned activity rather than a reaction to immediate news.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals regarding management's confidence. While this sale was pre-planned under a 10b5-1 plan, common in executive compensation strategies, it still represents a reduction in direct insider holdings.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries, including biotechnology, for executives to manage personal finances and diversify holdings without being accused of trading on material non-public information. For example, similar pre-planned sales are routinely observed at companies like Amgen or Gilead Sciences, where executives periodically monetize vested equity awards.

Stakeholder Impact

• Shareholders: The sale reduces the director's direct ownership, which could be interpreted in various ways, though the 10b5-1 plan mitigates negative interpretations.

Key Dates

Recommendation

This Form 4 details a pre-planned insider sale, which is a common occurrence for executives managing their compensation and personal finances. It does not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, 10b5-1 Plan